BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
456 results:

  • 1. A novel fluorescent probe based imprinted polymer-coated magnetite for the detection of imatinib leukemia anti-cancer drug traces in human plasma samples.
    Hashem HM; Ghaith EA; Eladl A; Abozeid SM; Abdallah AB
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jul; 315():124262. PubMed ID: 38613900
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
    Liu Y; Zhang S; Tan Y
    Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
    [No Abstract]    [Full Text] [Related]  

  • 3. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
    Fiskus W; Piel J; Collins M; Hentemann M; Cuglievan B; Mill CP; Birdwell CE; Das K; Davis JA; Hou H; Jain A; Malovannaya A; Kadia TM; Daver N; Sasaki K; Takahashi K; Hammond D; Reville PK; Wang J; Loghavi S; Sen R; Ruan X; Su X; Flores LB; DiNardo CD; Bhalla KN
    Blood; 2024 May; 143(20):2059-2072. PubMed ID: 38437498
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
    Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. CDK6: an attractive therapeutic target for T-ALL/LBL.
    Li W; Hu JK; Hu MG
    Expert Opin Ther Targets; 2023; 27(11):1087-1096. PubMed ID: 37975616
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
    Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
    Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
    Raetz EA; Teachey DT; Minard C; Liu X; Norris RE; Denic KZ; Reid J; Evensen NA; Gore L; Fox E; Loh ML; Weigel BJ; Carroll WL
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30609. PubMed ID: 37553297
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Artichoke as a melanoma growth inhibitor.
    Mathew AM; Deng Z; Nelson CJ; Mayberry TG; Bai Q; Lequio M; Fajardo E; Xiao H; Wakefield MR; Fang Y
    Med Oncol; 2023 Aug; 40(9):262. PubMed ID: 37544953
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
    Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
    Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia.
    Cao L; Ruiz Buendía GA; Fournier N; Liu Y; Armand F; Hamelin R; Pavlou M; Radtke F
    Blood Adv; 2023 Oct; 7(20):6240-6252. PubMed ID: 37358480
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic leukemia.
    Patel J; Gao X; Wang H
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Mellitin peptide quantification in seasonally collected crude bee venom and its anticancer effects on myelogenous K562 human leukaemia cell line.
    Obeidat M; Al-Khraisat IF; Jaradat DMM; Ghanim BY; Abdallah QM; Arqoub DA; Sabbah D; Al-Sanabra OM; Arafat T; Qinna NA
    BMC Complement Med Ther; 2023 Apr; 23(1):132. PubMed ID: 37098530
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
    Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
    Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
    Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
    Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Childhood cancer survival in the highly vulnerable population of South Texas: A cohort study.
    Wu S; Liu Y; Williams M; Aguilar C; Ramirez AG; Mesa R; Tomlinson GE
    PLoS One; 2023; 18(4):e0278354. PubMed ID: 37022991
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Xie X; Zhang W; Zhou X; Ye Z; Wang H; Qiu Y; Pan Y; Hu Y; Li L; Chen Z; Yang W; Lu Y; Zou S; Li Y; Bai X
    Br J Haematol; 2023 Jun; 201(5):940-953. PubMed ID: 36916190
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Trends in mortality and causes of death among Chinese adolescents aged 10-19 years from 1990 to 2019.
    Zhu J; Li Y; Zhang C; He J; Niu L
    Front Public Health; 2023; 11():1075858. PubMed ID: 36825144
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study.
    Aceves-Hernández JM; Inés Nicolás Vázquez M; Luis Garza Rivera J; Espinoza Godínez A; Mateo Flores J; de Jesús Cruz Guzmán J; Castaño VM
    Chem Biodivers; 2023 Mar; 20(3):e202200554. PubMed ID: 36799136
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.
    Tang J; Zhong J; Yang Z; Su Q; Mo W
    Biochem Biophys Res Commun; 2023 Apr; 650():96-102. PubMed ID: 36774689
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 23.